Egyptian health minister calls for stronger local drug manufacturing

Egyptian Health Minister Khaled Abdel Ghaffar urged stronger local pharmaceutical manufacturing to build resilient healthcare supply chains.

Abdel Ghaffar made the remarks at a healthcare supply chain event held on the sidelines of the 79th World Health Assembly in Geneva.

The minister noted that the COVID-19 pandemic exposed major weaknesses in healthcare supply systems such as excessive reliance on imports and weak local manufacturing.

Egypt's strategy rested on three pillars including digital integration linking more than 5,000 healthcare facilities and expanding local production to cover 85 to 90 percent of domestic medicine needs.

He also highlighted Egypt’s Drug Authority obtaining WHO Maturity Level 3 status and the success of the unified procurement system in reducing hepatitis C treatment costs.

Related Articles

Egypt’s Ministry of Health has held talks with a US pharmaceutical company to discuss investment in healthcare and drug manufacturing. The meeting aims to attract foreign capital and boost local production capacity.

Reported by AI

Egypt's Prime Minister Mostafa Madbouly chaired a high-level meeting on Sunday to review the availability of pharmaceutical products and active raw materials in the domestic market. The session, attended by ministers and officials, emphasized ensuring adequate strategic drug reserves and monitoring supply chains while advancing localization efforts. A detailed report confirmed sufficient inventories to meet local demand.

Egypt's Health Minister Khaled Abdel Ghaffar and Higher Education Minister Abdelaziz Konsowa held talks on integrating university hospitals into the Universal Health Insurance system, according to a statement from the health ministry. The step aims to strengthen institutional cooperation between the health and higher education sectors and position university hospitals as core partners in delivering services under Egypt's nationwide healthcare reform programme.

Reported by AI

Pharco Pharmaceuticals plans to invest around EGP 1.5bn next year, up from about EGP 1.15bn in 2025, to expand production capacity and strengthen its presence in domestic and export markets, Chairperson Sherine Helmy said. The company is prioritising improvements in product quality alongside expansion and diversification of production lines.

This website uses cookies

We use cookies for analytics to improve our site. Read our privacy policy for more information.
Decline